The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Seattle Genetics Inc

Nasdaq: SGEN
Last

(U.S.) $36.79

Today's change+0.14 +0.38%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.
 

Seattle Genetics Inc

Nasdaq: SGEN
Last

(U.S.) $36.79

Today's change+0.14 +0.38%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Seattle Genetics Inc up (U.S.)$0.14

Seattle Genetics Inc closed up Wednesday by (U.S.)$0.14 or 0.38% to (U.S.)$36.79. Over the last five days, shares have gained 1.52%, but are down 7.77% for the last year to date. Shares have underperformed the S&P 500 by 26.05% during the last year.

Key company metrics

  • Open(U.S.) $36.48
  • Previous close(U.S.) $36.65
  • High(U.S.) $36.96
  • Low(U.S.) $36.32
  • Bid / Ask-- / --
  • YTD % change-7.77%
  • Volume686,292
  • Average volume (10-day)927,117
  • Average volume (1-month)1,221,364
  • Average volume (3-month)1,130,269
  • 52-week range(U.S.) $30.80 to (U.S.) $55.99
  • Beta1.32
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.53
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-23.27%

Seattle Genetics Inc has a net profit margin of -23.27%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.77%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue76686867
Total other revenue--------
Total revenue76686867
Gross profit68626261
Total cost of revenue8767
Total operating expense91868583
Selling / general / administrative25262425
Research & development59545451
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-16-18-16-16
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-16-18-16-16
Income after tax-16-18-16-16
Income tax, total0000
Net income-16-18-16-16
Total adjustments to net income--------
Net income before extra. items-16-18-16-16
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-16-18-16-16
Inc. avail. to common incl. extra. items-16-18-16-16
Diluted net income-16-18-16-16
Dilution adjustment0000
Diluted weighted average shares124123123123
Diluted EPS excluding extraordinary itemsvalue per share-0.13-0.14-0.13-0.13
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.13-0.14-0.13-0.13